By Matthew Brady 
Korean healthcare AI company Lunit, a provider of solutions for cancer diagnostics and therapeutics, has acquired Volpara Health Technologies, a medical software provider for breast cancer screening.
The acquisition will allow Lunit to develop autonomous AI models that will independently screen, detect, and diagnose cancer, with the aim of enhancing patient care worldwide.
Lunit will integrate Volpara’s breast health platform with its AI-powered solutions for breast cancer detection, to result in a holistic AI suite that enhances every aspect of breast screening, including detection capabilities and administrative processes.
The acquisition also facilitates expansion into the US market, where Volpara has a presence in more than 2,000 medical sites. In turn, Lunit plans to promote Volpara’s solutions across Europe, Asia, the Middle East, and South America,
In April 2024, Lunit agreed a strategic partnership with Denmark-based Radiobotics, a musculoskeletal AI diagnostics provider.